Aflibercept for Macular Oedema With Underlying Retinitis Pigmentosa (AMOUR) Study
Status:
Unknown status
Trial end date:
2017-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and efficacy of intravitreal injections of
Aflibercept (Eylea) in treating Cystoid Macula Oedema (CMO) in patients with underlying
Retinitis Pigmentosa (RP).